Home LiteratureArticle Details
PMID: 856872 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.

The Journal of clinical investigation ·Vol. 59 ·No. 5 ·1977-05-00 ·Pages 879-88

Craddock PR, Fehr J, Dalmasso AP, Brighan KL, Jacob HS

Abstract

Acute leukopenia occurs in all patients during the first hour of hemodialysis with cellophanemembrane equipment. This transient cytopenia specifically involves granulocytes and monocytes, cells which share plasma membrane reactivity towards activated complement components. The present studies document that complement is activated during exposure of plasma to dialyzer cellophane, and that upon reinfusion of this plasma into the venous circulation, granulocyte and monocyte entrapment in the pulmonary vasculature is induced. During early dialysis, conversion of both C3 and factor B can be demonstrated in plasma as it leaves the dialyzer. Moreover, simple incubation of human plasma with dialyzer cellophane causes conversion of C3 and factor B, accompanied by depletion of total hemolytic complement and C3 but sparing of hemolytic C1. Reinfusion of autologous, cellophane-incubated plasma into rabbits produces selective granulocytopenia and monocytopenia identical to that seen in dialyzed patients. Lungs from such animals reveal striking pulmonary vessel engorgement with granulocytes. The activated complement component(s) responsible for leukostasis has an approximate molecular weight of 7,000-20,000 daltons. Since it is generated in C2-deficient plasma and is associated with factor B conversion, it is suggested that activation of complement by dialysis is predominantly through the altermative pathway.

MeSH Terms
Adult Animals Blood Cell Count Cellophane/adverse effects Complement System Proteins/physiology Granulocytes Humans Leukocyte Adherence Inhibition Test Leukopenia/etiology Lung/blood supply Rabbits Renal Dialysis/adverse effects Zymosan/adverse effects
Chemicals
Cellophane Complement System Proteins Zymosan
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Craddock P R
Fehr J
Dalmasso A P
Brighan K L
Jacob H S
References (38)
38 references, click to expand
  1. Interaction of complex polysaccharides with the complement system: effect of calcium depletion on terminal component consumption.
    Infect Immun. 1975 Feb;11(2):273-9 PMID: 46215
  2. Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge.
    J Clin Invest. 1975 May;55(5):967-74 PMID: 1123432
  3. Complement-mediated granulocyte dysfunction in paroxysmal nocturnal hemoglobinuria.
    Blood. 1976 Jun;47(6):931-9 PMID: 1276474
  4. Estimation of the molecular weights of proteins by Sephadex gel-filtration.
    Biochem J. 1964 May;91(2):222-33 PMID: 4158310
  5. Further studies on the chemotactic factor of complement and its formation in vivo.
    Immunology. 1966 Aug;11(2):141-53 PMID: 4162237
  6. A plasmin-split fragment of C'3 as a new chemotactic factor.
    J Exp Med. 1967 Aug 1;126(2):189-206 PMID: 4226271
  7. C3 shunt activation in human serum chelated with EGTA.
    J Immunol. 1972 Oct;109(4):807-9 PMID: 4627510
  8. A new subcutaneous arteriovenous shunt: applicable in cases where the standard Quinton-Scribner shunt and arteriovenous fistula have failed.
    Surgery. 1973 Apr;73(4):512-20 PMID: 4632150
  9. Hemodialysis coil-induced transient neutropenia and overshoot neutrophilia in normal man.
    Blood. 1973 Mar;41(3):399-408 PMID: 4690139
  10. Interactions of the complement system with endotoxic lipopolysaccharide. Generation of a factor chemotactic for polymorphonuclear leukocytes.
    J Exp Med. 1968 Aug 1;128(2):259-75 PMID: 4873021
  11. A simple method for anticoagulation during pre- and postoperative hemodialysis, avoiding rebound phenomenon.
    Surgery. 1972 Oct;72(4):630-3 PMID: 5057654
  12. The separation of nine components and two inactivators of components of complement in humansserum.
    Immunochemistry. 1970 Jan;7(1):43-61 PMID: 5416393
  13. Profound neutropenia during the early phase of hemodialysis.
    JAMA. 1968 Mar 25;203(13):1135-7 PMID: 5694348
  14. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.
    Immunochemistry. 1966 Mar;3(2):111-35 PMID: 5960883
  15. Cannulation of blood vessels for prolonged hemodialysis.
    Trans Am Soc Artif Intern Organs. 1960 Apr 10-11;6:104-13 PMID: 13738750
  16. STUDIES ON THE TERMINAL STEPS OF IMMUNE HEMOLYSIS. I. INHIBITION BY TRISODIUM ETHYLENEDIAMINETETRAACETATE (EDTA).
    J Immunol. 1964 Sep;93:409-13 PMID: 14218598
  17. Function of h(2)o(2), myeloperoxidase, and hexose monophosphate shunt enzymes in phagocytizing cells from different species.
    Infect Immun. 1970 Apr;1(4):338-44 PMID: 16557739
  18. Hemodialysis leukopenia and polymorph random mobility-a possible correlation.
    J Lab Clin Med. 1975 Feb;85(2):191-7 PMID: 803539
  19. Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies.
    Ann Intern Med. 1975 Sep;83(3):330-6 PMID: 1190631
  20. The complement system of man. I.
    N Engl J Med. 1972 Sep 7;287(10):489-95 PMID: 4114930
  21. Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator.
    J Exp Med. 1973 May 1;137(5):1109-23 PMID: 4121926
  22. The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.
    J Exp Med. 1966 Jan 1;123(1):33-54 PMID: 4159289
  23. Lysosomal enzyme release from human leukocytes: mediation by the alternate pathway of complement activation.
    J Immunol. 1973 Jul;111(1):33-7 PMID: 4197335
  24. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.
    J Immunol. 1970 Jul;105(1):55-69 PMID: 4246566
  25. Mechanisms of lysosomal enzyme release from human leukocytes: microtubule assembly and membrane fusion induced by a component of complement.
    Proc Natl Acad Sci U S A. 1973 Oct;70(10):2916-20 PMID: 4355374
  26. The lysis of paroxysmal nocturnal haemoglobinuria red cells by serum and cobra factor.
    Br J Haematol. 1972 Dec;23(6):693-705 PMID: 4630453
  27. Kinetics of stagnation-induced neutropenia during hemodialysis.
    Trans Am Soc Artif Intern Organs. 1972;18(0):305-11 PMID: 4679883
  28. Accelerated atherosclerosis in prolonged maintenance hemodialysis.
    N Engl J Med. 1974 Mar 28;290(13):697-701 PMID: 4813742
  29. New biological activity following intravascular activation of the complement cascade.
    Nature. 1974 Jun 28;249(460):841-3 PMID: 4834789
  30. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.
    J Immunol. 1969 Nov;103(5):944-52 PMID: 4981797
  31. Mechanisms of recovery from neutropenia induced by hemodialysis.
    Blood. 1971 Nov;38(5):623-31 PMID: 5094585
  32. Pulmonary bed sequestration of neutrophils during hemodialysis.
    Blood. 1970 Sep;36(3):337-40 PMID: 5451923
  33. Leukocyte dynamics with three types of hemodialyzers.
    Trans Am Soc Artif Intern Organs. 1969;15:45-9 PMID: 5791427
  34. Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula.
    N Engl J Med. 1966 Nov 17;275(20):1089-92 PMID: 5923023
  35. Systemic lupus erythematosus: a clinical report of 47 cases with pathologic findings in 18.
    Am J Med Sci. 1958 Sep;236(3):318-29 PMID: 13571239
  36. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes.
    J Exp Med. 1962 Mar 1;115:453-66 PMID: 13872176
  37. The properdin system and immunity. XII. Assay, properties and partial purification of a hydrazine-sensitive serum factor (factor A) in the properdin system.
    Z Immun exp ther. 1959 Oct-Nov;118:329-48 PMID: 14431638
  38. Artificial kidney function; kinetics of hemodialysis.
    J Clin Invest. 1951 Oct;30(10):1062-70 PMID: 14888684
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1977-05-00
Pages
879-88
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC372296
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]